Is GMED a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on NuVasive integration and operating leverage, with revenue (ttm) at ~$3.14 billion. The bear case rests on the largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. Analysts covering it are spread from $84.00 to $125.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $84.00, -2.2% from the $85.90 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

NuVasive integration and operating leverage. The merger's promised cost synergies are now showing up in reported numbers rather than slides, with adjusted EBITDA margin near 35% and non-GAAP EPS growing several times faster than revenue. The most optimistic analyst target on GMED is $125.00, +45.5% from the $85.90 price. That figure is only reachable if this thesis works close to its best case.

The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. Competition is heavy on both flanks, with Medtronic and its Mazor platform on one side and fast-growing challengers such as Alphatec taking surgeon share on the other, and the surgeon-recruiting lever that drives current outperformance can run in reverse. Regulatory exposure is concrete rather than theoretical: the July 2024 FDA warning letter concerning ExcelsiusGPS complaint handling and medical device reporting is the kind of matter that can escalate to consent decrees or shipment holds if not resolved. Nevro is shrinking, and management's own recovery timeline extends into late 2026, so an impairment is possible if trial volumes stay weak. Plaintiff firms have publicly announced investigations following the 2025 revenue miss and the FDA letter, and product-liability activity around spinal cord stimulators adds separate legal cost that is hard to size in advance. The most pessimistic published target is $84.00, -2.2% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

The second largest spine implant company after the NuVasive merger, pairing implants with the ExcelsiusGPS surgical robot.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (NuVasive integration and operating leverage) stalling in the reported numbers rather than in the narrative, the risk above (the largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Mostly spinal implants and the instruments used to place them: pedicle screws, interbody cages, cervical plates and expandable devices, sold to hospitals and surgery centers through a largely direct sales force. On top of that sits enabling technology, principally the ExcelsiusGPS robotic navigation system, Excelsius3D imaging and the Excelsius Flex knee robot. Since April 2025 it also sells Nevro spinal cord stimulators for chronic pain. Implants and disposables, not robots, generate the large majority of revenue.

An implant company that uses robotics commercially. Robot capital sales are a small slice of revenue; the strategic value of an ExcelsiusGPS placement is that the hospital then standardizes on Globus implants for the procedures done on it. That makes the installed base a distribution asset with switching costs attached, which is why the company reports enabling-technology placements as a leading indicator rather than as a profit center in its own right.

The all-stock merger closed in September 2023 and roughly doubled Globus's revenue, making it the second largest spine company in the world behind Medtronic and giving it a much larger international footprint. The financial payoff has come more through cost synergies than through revenue: Q2 2026 adjusted EBITDA margin of about 35.4% was up roughly 740 basis points year over year while revenue grew about 6%. Merger amortization is also why GAAP and non-GAAP earnings differ so widely.